Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 8/20 | 0.53 |
| ▸ | ROCK2 | O75116 | 12/20 | 0.48 |
| ▸ | WNT1 | P04628 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | HTR3A | P46098 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17452676 | 0.91 | ROCK1 (0.52) | ROCK1ROCK2DYRK1AHTR3A | |
| SCHEMBL17437940 | 0.90 | ROCK1 (0.50) | ROCK1ROCK2WNT1DYRK1AHTR3A | |
| SCHEMBL17437882 | 0.89 | ROCK1 (0.51) | ROCK1ROCK2WNT1DYRK1AHTR3A | |
| SCHEMBL17437985 | 0.89 | ROCK1 (0.55) | ROCK1ROCK2HTR3A | |
| SCHEMBL17437996 | 0.89 | ROCK1 (0.47) | ROCK1ROCK2DYRK1AHTR3A | |
| SCHEMBL17438021 | 0.88 | ROCK2 (0.49) | ROCK1ROCK2HTR3A | |
| SCHEMBL17452536 | 0.88 | ROCK2 (0.49) | ROCK1ROCK2HTR3A | |
| SCHEMBL17437832 | 0.88 | ROCK1 (0.49) | ROCK1ROCK2HTR3A | |
| SCHEMBL17438139 | 0.88 | ROCK1 (0.55) | ROCK1ROCK2 | |
| SCHEMBL17452673 | 0.88 | ROCK2 (0.49) | ROCK1ROCK2HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9902702-B2 | Spirocycloheptanes as inhibitors of rock | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-02-27 | — | — | US | disclosed |
| US-20160016914-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | BRISTOL-MYERS SQUIBB COMPANY | 2016-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016914-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | ROCK1, MYLK, ROCK2 | ROCK1 1/4885ROCK2 3/4885WNT1 974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.